No Data
No Data
Revenues Not Telling The Story For Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) After Shares Rise 37%
Kunming Longjin Pharmaceutical: 2024 Interim Performance Forecast
*Special Treat Longjin (002750.SZ): Expected to lose between 3.6 million yuan and 4.9 million yuan in the first half of the year.
On July 10th, Gelunhui reported that *ST Longjin (002750.SZ) announced its performance forecast for the first half of 2024, with a net loss of 3.6 million yuan to 4.9 million yuan attributable to shareholders of the listed company, compared with a loss of 15.7777 million yuan in the same period last year. After deducting non-recurring gains and losses, the net loss was 9.7 million yuan to 13.15 million yuan, compared with a loss of 19.4725 million yuan in the same period last year. The basic earnings per share were expected to be between a loss of 0.0090 yuan/share and a loss of 0.0122 yuan/share. Due to the continued impact of policy factors such as medical insurance payment restrictions, hospital prescription restrictions, and the company's injection of scutellaria baicalensis extract price reduction by 67%.
Longjin Pharmaceutical (002750.SZ): Net loss of 4.4918 million yuan in the first quarter
Gelonghui, April 29 | Longjin Pharmaceutical (002750.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 26.3884 million yuan, up 22.43% year on year; net profit attributable to shareholders of listed companies was 4.4918 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 6.1091 million yuan; basic earnings per share - 0.0112 yuan.
More Unpleasant Surprises Could Be In Store For Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) Shares After Tumbling 29%
Here's Why We're Not Too Worried About Kunming Longjin Pharmaceutical's (SZSE:002750) Cash Burn Situation
No Data